uPAR-CAR-T Senolytic Immunotherapy
Idiopathic Pulmonary Fibrosis · CAR-T cells targeting uPAR (urokinase plasminogen activator receptor) on senescent cells — living drug senolytic
Mechanism
CAR-T cells targeting uPAR (urokinase plasminogen activator receptor) on senescent cells — living drug senolytic
Development stage
Preclinical (MSK)
Evidence level
Level 2 (Preclinical→Phase I)
Developer
Memorial Sloan Kettering
Overview
Nature Aging 2023: single low-dose uPAR-CAR-T reversed liver fibrosis, improved exercise capacity in aged mice. Long-lasting prophylactic effect — a one-time living senolytic. Cell 2026: uPAR ecosystem approach overcomes antigen heterogeneity. LNP-delivered in-vivo CAR approach eliminates manufacturing bottleneck.
Explore related
Medical disclaimer. This page summarizes research about uPAR-CAR-T Senolytic Immunotherapy for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.